Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening

CMAJ. 2010 Mar 23;182(5):476-80. doi: 10.1503/cmaj.090401. Epub 2009 Nov 23.

Authors

Suran L Fernando¹, Andrew J Broadfoot

Affiliation

¹ PaLMS Immunorheumatology Laboratory, Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Reserve Rd, St. Leonards, Sydney, NSW 2065, Australia. sfernando@nsccahs.health.nsw.gov.au

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Alleles
Allopurinol / adverse effects*
Anticonvulsants / adverse effects
Asian People / genetics
Carbamazepine / adverse effects
China
Cyclosporine / therapeutic use
Drug Hypersensitivity / genetics*
Genetic Predisposition to Disease
Genetic Testing*
Gout Suppressants / adverse effects*
HLA-B Antigens / genetics
Humans
Immunization, Passive
Immunosuppressive Agents / therapeutic use
Keratoconjunctivitis / chemically induced
Keratoconjunctivitis / drug therapy
Male
Stevens-Johnson Syndrome / chemically induced*
Stevens-Johnson Syndrome / drug therapy
Stevens-Johnson Syndrome / etiology*
Urethritis / chemically induced
Urethritis / drug therapy

Substances

Anticonvulsants
Gout Suppressants
HLA-B Antigens
Immunosuppressive Agents
Carbamazepine
Allopurinol
Cyclosporine